Dec 10, 2016 Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARα Agonist in Genomically Defined Subsets of Breast Cancer
Dec 5, 2016 Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARα Agonist for Genomically Defined Subsets of AML and MDS Patients
Nov 21, 2016 Syros Pharmaceuticals Announces Late-Breaking Presentation on SY-1425 at San Antonio Breast Cancer Symposium
Nov 14, 2016 Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Nov 3, 2016 Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RARα Agonist, at the ASH Annual Meeting